SMMT
Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) has 3 SEC Form 4 filings (3 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jun 12, 2026.
Insiders have net bought $101.4M over the trailing 6 months. The largest single insider purchase in this window was $50.0M by Co-Chief Executive Officer Zanganeh Mahkam on Jun 12, 2026.
- Industry:Biotechnology
- CEO:Robert W. Duggan
- Employees:159
- HQ:Cambridge, MA, US
- IPO:2015-03-05
Insider Buying
$101.4M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$11.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Co-Chief Executive Officer | Purchase | 3,810,000 | $50.0M | Jun 12 | SEC ↗ | |
| Co-Chief Executive Officer | Purchase | 3,810,000 | $50.0M | Jun 12 | SEC ↗ | |
Zanganeh MahkamFirst filing | Co-Chief Executive Officer | Purchase | 100,000 | $1.5M | Jun 4 | SEC ↗ |
Related companies
Summit Therapeutics Inc. is in the Healthcare sector.